Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
When evaluating generic drug stocks, investors often look at the Forward Twelve Months (P/E F12M) ratio, which is based on projected earnings. This forward-looking metric can provide insights into the expected performance of generic drug manufacturers.
Financials are very good for long term.
It depends on whether he skips his meds. He will now beat Eltp up as much as he can whilst dreaming of his interest payments.
Elite now has total 85,000 square feet of operational floor space. Nice! speaking of "EXPANSION"
Excellent post thank you I really don’t have time to mess with the goat land people
People want to buy everything on sale… except stocks.
Good point. Thanks
It’s a non-cash item so an investor shouldn’t really care as it’s a below the line exclusion.
I am thrilled Elite cleaned up the books and issued those 50M shares to the CEO, those shares were on last year’s 2022 10K as owed but not issued. The 50M shares also generated a loss each quarter for the last year due to the stock price increasing each quarter. Change in fair value of stock-based liabilities is driven by stock price from the quarter at the beginning period vs the price at the end of the quarterly period … see page 49. Per the report fair value of stock-based liabilities in 2024 showed a loss of (5,743,468) but 2023 showed 0. If the stock price increased each quarter, it generated a loss but in the prior years when quarterly stock price decreased it would generate income; for example, 2023 was zero.
You have the same issue with the outstanding warrants, but they will stay on the books until the CEO executes the warrants.
Happy 4th of July
Hey, I'm on vacation. Enjoy your job. Stock options for employees. Payment of services agreed in shares from awhile ago? You know people can read the filings. Right?
You have to get better at this. It's boring.
Company's keeps driving numbers. You have to harass people. sad ... 😭..lol
After reading that jumble of words, I think I'm gonna be ok. I don't feel dumberer. Lol
As of March 31, 2023, there were 1,014,015,081 shares of Common Stock issued and 1,013,915,081 shares of Common Stock outstanding.
Common Stock issued as of March 31, 2024 and 2023, respectively 2024: 1,068,373,108 2023: 1,014,015,081
54,358,027 additional shares added in the past year !!!!!!!!!!
How is this good for us ????????? Seriously,
IB_🤴🏻
Consolidated revenues for Fiscal 2024 were $56.6 million, an increase of $22.4 million or approximately 65% as compared to the comparable period of the prior fiscal year. Operating profits were $10.8 million, an increase of $7.1 million or approximately 192% from the comparable period of the prior year, and net income attributable to common shareholders was $20.1 million. The increase in operating profits was primarily attributed to the commercial launch of the Elite label product line during Fiscal 2024.
Keep it down keep it down gonna put in another $30,000 worth by end of August no matter what the PPS is
Have you calculated today’s loss on your 6 trillion shares? Lmao idiot
You don't have any holdings. It's funny when you say that tho.
The only number that means anything is the stock price Period Pe means crap you don’t make money on the pe The market lists share price every dai in the papers and on the NYSE why don’t they just list or instead You are a fool who keeps adding and topping off for 10 years You have zero cred buf
There are several formulae our there:
One says: The P/E Ratio—or “Price-Earnings Ratio”—is a common valuation multiple that compares the current stock price of a company to its earnings per share (EPS).
Stock Price: 18.7
Earning Per Share: 2
P/E Ratio: 9.35
Yahoo says: 9.94
Leasing costs don’t hit COGS. I think it went down due to shifting some volume to Prasco at lower margin rate.
I mentioned the other day the risk of this and impact to margin rate. I got laughed at and what did the Zack’s article end with?
“Gross margin contraction does not bode well.”
This is always top of mind to an investor that understands financials. This has a real financial impact.
This on top of the lackluster messaging is what is impacting the stock today.
The company is doing phenomenal. We unfortunately have a CEO headwind that doesn’t know what to communicate to the investment community and the share price gets stung almost every single time. Lack of solid IR isn’t helping.
Go right ahead and buy all the stock you want It doesn’t do a thing to my holdings Take off the blinders This stock is going nowhere soon Same stuff every cc Waitbtill the next one Already waiting about 10 years for the famous quote “we will be in dollar land in a year Dollar land really you can’t even get to 25 cent land
Have you calculated the PE ratio ??
THX
To anyone new here, this message board is orchestrated theatre by overseas folks that are required to be here. Listen to the conf calls. Read the financials. Do basic math. Stock is going up and should be 2x where it is now
Can you tell me the yoy revenue and margin for the part three years?
I know you aren't allowed to say but thought it would be fun to ask.
Great call. Great numbers. Let's launch the next four....
Still couldn't find a better job then coming to a message board on a stock you know nothing about for years and years? You are the best reason to buy this stock and don't even understand why.
I’m not worried about the stock price now or even in 6 months. Elite will continue to execute on their business strategy regardless of their poor messaging.
It’s always been a pump and dump
Why did he blow off the Mikah question? He didn’t even answer it He said it was just rhetoric The question was should Mikah be bought out of its half
The gross margin went down because of the new facility and the lease of the new machines.
Why next 6 months ? 6 months most everyone was saying Just wait till July numbers and cv Well we did And what do we have Stock down to 18
Elite Pharmaceuticals' (ELTP) FY24 Earnings Up, Gross Margin Down
Elite Pharmaceuticals, Inc. (ELTP Quick QuoteELTP - Free Report) delivered earnings per share (EPS) of 2 cents in fiscal 2024 compared with break-even EPS at the fiscal 2023-end.
Revenues in Detail
Elite Pharmaceuticals registered revenues of $56.6 million in fiscal 2024, up 65.8% from the comparable fiscal 2023 period. primarily resulted from robust revenues from Manufacturing fees.
Segment Details
Elite Pharmaceuticals’ derives revenues from two sources — Manufacturing fees and Licensing fees.
In fiscal 2024, revenues from Manufacturing fees were $54.1 million, up 85.4% from the fiscal 2023-end. This primarily resulted from the launch of the Elite label during the current fiscal year, which achieved increased sales for the year ended Mar 31, 2024, compared with the prior fiscal year, which did not include any sales of Elite label products.
Revenues in the Licensing fees segment totaled $2.5 million in fiscal 2024, down 49.6% from fiscal 2023. The decrease was primarily due to the expiration of the marketing alliance agreements between the company and Lannett Company, Inc. (the Lannett Agreements) on Mar 31, 2023.
The revenue streams that were generated during periods ending on or prior to Mar 31, 2023, and attributed to the Lannett Agreements included profit splits on the sale by Lannett of Amphetamine IR and Amphetamine ER. Since Apr 1, 2023, these products have been sold by Elite Pharmaceuticals under its label, with revenues being recorded as manufacturing revenues instead of licensing fees....
https://www.zacks.com/stock/news/2296264/elite-pharmaceuticals-eltp-fy24-earnings-up-gross-margin-down#:~:text=Elite%20Pharmaceuticals'%20Gross%20Margin,the%20comparable%20fiscal%202023%20period.
Although I don't agree with the statement highlighted in blue and some parts, its somewhat okay to get a news from other media source.
It was an amazing call. Messaging and market maker hitting stop losses is my guess. Lots to enjoy over the next 6 months.
All you clown car lottery winners If things are so great ,best results ever and best cc why is the pos down terrible today Guess the market doesn’t agree with you Keep toppin off lol
easy 5x minimum. Honestly, 8x is my minimum call. Absolute minimum.
Yeah, it looks like I have to put ELTP Princess on ignore as well now. I have the rest of them ignored.
This Registration Statement on Form S-8 (“Registration Statement”) is being filed by Elite Pharmaceuticals, Inc., a Nevada corporation (the “Company”), for the purpose of registering an additional 12,730,000 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”) that were added to the shares authorized for issuance under the Elite Pharmaceuticals, Inc. Restated 2014 Equity Incentive Plan (“Equity Incentive Plan”) for which a Registration Statement on Form S-8 relating to the same employee benefit plan is effective. Pursuant to General Instruction E to Form S-8, with respect to the Equity Incentive Plan, the contents of the Registration Statement on Form S-8 (File No. 333-197694) on July 29, 2014 is incorporated herein by reference except to the extent supplemented, amended or superseded by the information set forth herein. Only those items of Form S-8 containing new information not contained in the earlier registration statements are presented herein.
https://www.sec.gov/Archives/edgar/data/1053369/000149315224025859/forms-8.htm
By registering these shares on Form S-8, it permits the holder(s) to sell them in the open market
During the years ended March 31, 2024 and 2023, the Company issued 54,358,027 and 2,633,093 shares of Common Stock, respectively, as payment in directors fees, salaries, and consulting fees
Millions and millions of new shares being dished out by the CEO like a croupier dealer
Only retail isnt getting a sniff
So retails ownership in Elite drops lower and lower.
Some of those improved revs and earnings being eaten up by dilution
But hey, load the boat no matter what, its about to get real, Hammer TIme
I just hope there aren't millions more shares made up in the next six weeks to line Directors pockets !!!!!!!!!!!!!
You getting any of those new 54+ Million shares ????????????
IB_🤴🏻
Four new ANDAs acquired after last reporting period
This is going to get Real !!!! in 6 weeks.
Im ready for the next Earnings game .
Bashers don't hurt the share price, NasRat's dilution does !!!!!!!!!!!!!!!!!!!!!!!!!!
He gives a good earnings report and then shoots the retail shareholders in the foot with well over 50 Million shares going to who ... HuH ... Who are those 54 Million shares going to ???? Are YOU getting any ???????????????????
IB_🤴🏻
I thought you said never. SMH.
And red as blood, now what ??
It looks like most of your " long" brethren are liars.
Big day for the lowly day trader...ouch.
Absolutely hilarious.
This thing was hyped so high, no amount of good news could ever compare.
There are several obvious trolls and bashers posting here.
Why do the investors who believe in this stock bother to have conversations with them.
Put them all on ignore and get rid of much of the junk on this board.
Transferring an additional $10K to Fidelity...
we need the ultimate ruler at the rescue for FFTFC
Followers
|
969
|
Posters
|
|
Posts (Today)
|
255
|
Posts (Total)
|
402991
|
Created
|
03/24/09
|
Type
|
Free
|
Moderators jimr1717 mrwrn2010 NASDAQ2020 IB_ namtae Dr JoeBarducci |
Senior Moderator: IB_
Posted: 7/02/2024
________________________________________________________________________________________________________________
Elite Pharmaceuticals, Inc. |
Website | Location | Employees | Facility | CEO |
www.elitepharma.com | Northvale, New Jersey | 64 | 55,000 sq ft | Nasrat Hakim |
Products & Pipeline | ||||
Drug | Market Size | Status | Competitors | Marketed By |
Adderall IR | 389.8 M | On Market | 15 | Elite |
Adderall XR | 1.56 B | On Market | 10 | Elite & Prasco |
Dantrolene | 6.3 M | On Market | 2 | Elite |
Isradipine | 5.5 M | On Market | 1 | Elite |
Loxapine | 5 M | On Market | 2 | Elite |
Phendimetrazine | 4.5 M | On Market | 4 | Elite |
Trimipramine | 2 M | On Market | 1 | Elite |
Naltrexone | 16 M | On Market | 5 | Precision Dose |
Phentermine Capsules | 7.5 M | On Market | 6 | Precision Dose |
Phentermine Tablets | 40 M | On Market | 8 | Precision Dose |
Vigabatrin | 233.7 M | On Market | 13 | Pyros |
Doxycycline | 85 M | Approved (Discontinued) | 9 | ---------- |
Tylenol with Codeine | 45 M | Approved | 5 | ---------- |
Dopamine Agonist | 12 M | Filed with FDA - 22 Dec 2022 | ---------- | ---------- |
Methotrexate | 64.3M | Approved - 16 May 2024 | 8 | Elite |
Percocet | 500 M | Approved | ---------- | |
Norco | 477 M | Approved | ---------- | |
Methadone | 30 M | Approved | ---------- | |
OxyContin | 720 M | Filed with FDA - 17 Aug 2023 | ---------- | ---------- |
Vyvanse | 5.1 B | Filed with FDA - 21 Dec 2023 | 14 | ---------- |
Concerta | 1.16 B | In Development (Final Stages) | 9 | ---------- |
Financials | ||||
Fiscal Year | Revenue | Change | Net Income | Change |
2019 | 7,568,508 | ---------- | (9,279,321) | ---------- |
2020 | 17,994,639 | +137.76% | (2,240,351) | +75.86% |
2021 | 25,380,749 | +41.05% | 5,088,421 | +327.13% |
2022 | 32,262,117 | +27.11% | 8,898,245 | +74.87% |
2023 | 34,155,114 | +5.87% | 3,561,846 | -59.97% |
2024 | 56,625,128 | +65.79% | 20,108,631 | +464.56% |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |